Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Abrisqueta · SciRah

Researcher profile · Semantic Scholar

P. Abrisqueta

Share profile

P. Abrisqueta — researcher profile on SciRah

h-index: 35
Works: 320
Citations: 5,274

Most-cited papers

Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.
Gilles Crochet, G. Iacoboni, Audrey Couturier, E. Bachy +22 more
2024Blood61 citations Open access
Semantic Scholar
Treatment outcomes in patients with large B‐cell lymphoma after progression to chimeric antigen receptor T‐cell therapy
G. Iacoboni, J. Iraola-Truchuelo, M. O'Reilly, Víctor Navarro +30 more
2024HemaSphere41 citations Open access
Semantic Scholar
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma
Franck Morschhauser, G. Salles, Laurie H. Sehn, Alex F. Herrera +33 more
2025Journal of Clinical Oncology37 citations Open access
Semantic Scholar
New Insights into First-Line Therapy in Diffuse Large B-Cell Lymphoma: Are We Improving Outcomes?
P. Abrisqueta
2024Journal of Clinical Medicine21 citations Open access
Semantic Scholar
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment
G. Iacoboni, Víctor Navarro, P. Sesques, K. Rejeski +27 more
2024Journal of Hematology & Oncology16 citations Open access
Semantic Scholar
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
P. Abrisqueta, E. González-Barca, C. Panizo, José María Arguiñano Pérez +12 more
2024The Lancet Haematology15 citations Open access
Semantic Scholar
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma
L. Falchi, A. Sureda, S. Leppä, J. Vermaat +18 more
2025Blood13 citations Open access
Semantic Scholar
Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Y. Karimi, P. Abrisqueta, S. de Vos, M. Nijland +7 more
2024Journal of Clinical Oncology12 citations
Semantic Scholar
Kinetics of cellular and humoral immunogenicity and effectiveness of SARS‐CoV‐2 booster vaccination in hematologic neoplasms
M. Jiménez, C. Fernández-Naval, V. Navarro, S. Novoa +19 more
2023American journal of hematology/oncology11 citations Open access
Semantic Scholar
S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS
A. Sureda, L. Falchi, S. Leppa, J. Vermaat +15 more
2023HemaSphere11 citations Open access
Semantic Scholar
Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy
G. Iacoboni, K. Rejeski, Víctor Navarro, T. van Meerten +20 more
2025Leukemia8 citations Open access
Semantic Scholar
Epcoritamab with rituximab + lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7.
Leslie A. Lori, L. Falchi, J. Vermaat, G. Musuraca +10 more
2024Journal of Clinical Oncology7 citations Open access
Semantic Scholar
Impact of SCHOLAR-1 criteria on CAR-T cell therapy efficacy in aggressive B lymphoma. A real-world GELTAMO/GETH study.
M. B. Oreiro, Antonio Gutiérrez, G. Iacoboni, L. Corral +21 more
2023Transplantation and Cellular Therapy7 citations Open access
Semantic Scholar
Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL
Š. Pavlová, J. Malčíková, Lenka Radova, Silvia Bonfiglio +95 more
2025HemaSphere6 citations Open access
Semantic Scholar
Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study
L. Bento, Antonio Gutiérrez, C. Martinez, M. C. O. Verdet +35 more
2025Blood Advances5 citations Open access
Semantic Scholar
Genetic subtyping by Whole Exome Sequencing across Diffuse Large B Cell Lymphoma and Plasmablastic Lymphoma
A. A. Pomares, L. R. Merino, S. Gonzalez, Jordi Morata +15 more
2025PLoS ONE5 citations Open access
Semantic Scholar
Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO
Antonio Gutiérrez, I. Zeberio, F. Peñalver, P. Martinez-Barranco +37 more
2025Blood Advances5 citations Open access
Semantic Scholar
The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potential
Miriam Verdú-Bou, Maria Joao Baptista, M. L. Ribeiro, Aleix Méndez-López +21 more
2025Blood Advances5 citations Open access
Semantic Scholar
A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma
P. Mozas, S. Casanueva-Eliceiry, A. Rivero, Á. Serna +17 more
2023Hematological Oncology5 citations Open access
Semantic Scholar
Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma
G. Iacoboni, E. Kyvsgaard, V. Navarro, D. Russler-Germain +29 more
2026Blood Advances4 citations Open access
Semantic Scholar
EPCORITAMAB + R‐ICE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION: EPCORE NHL‐2
S. de Vos, D. Morillo, R. Córdoba, P. Prieto +14 more
2025Hematological Oncology4 citations
Semantic Scholar
Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia
D. Medina-Gil, Laura Palomo, Víctor Navarro, Gonzalo Lázaro +17 more
2025Haematologica4 citations Open access
Semantic Scholar
ABCL-404: First Disclosure of Epcoritamab+R-ICE in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Eligible For Autologous Stem Cell Transplantation (ASCT): EPCORE NHL-2
M. Trněný, R. Córdoba, S. de Vos, P. Prieto +14 more
2025Clinical Lymphoma, Myeloma & Leukemia4 citations
Semantic Scholar
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC).
Á. Medina, A. Muntañola, M. Crespo, Ángel Ramírez +12 more
2025Medicina clínica (Ed. impresa)4 citations
Semantic Scholar
ABCL-417 First Data From Subcutaneous Epcoritamab + Polatuzumab Vedotin Rituximab, Cyclophosphamide Doxorubicin, and Prednisone (Pola-RCHP) for First-Line Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE NHL-5
Daniel Alan Kerr, D. Lavie, A. Avigdor, I. Avivi +12 more
2024Clinical Lymphoma, Myeloma & Leukemia4 citations
Semantic Scholar
Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes
Á. Serna, Víctor Navarro, G. Iacoboni, Laia López +16 more
2024Haematologica4 citations Open access
Semantic Scholar
A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial
C. Carpio, F. de la Cruz-Vicente, Ramón García-Sanz, I. Zeberio +14 more
2025British Journal of Haematology3 citations
Semantic Scholar
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study
A. Visentin, E. Gaffo, M. Fürstenau, Kerry A. Rogers +44 more
2025Leukemia3 citations Open access
Semantic Scholar
Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B‐Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical Review
B. von Tresckow, P. Abrisqueta, I. Zamanillo, Á. Serna +16 more
2025European Journal of Haematology3 citations Open access
Semantic Scholar
Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders
Á. Serna, V. Navarro, M. Jiménez, J. Iraola-Truchuelo +16 more
2025Blood Advances3 citations
Semantic Scholar
Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in patients with Waldenström macroglobulinemia: Updated results from an ongoing Phase 1a/b study
Nirav Shah, Scott Huntington, D. Lewis, T. Munir +13 more
2025Blood3 citations
Semantic Scholar
First Data From Subcutaneous Epcoritamab + Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) for First-Line Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE NHL-5
D. A. Kerr, D. Lavie, A. Avigdor, I. Avivi +14 more
2024Clinical Lymphoma, Myeloma & Leukemia3 citations
Semantic Scholar
Abstract CT174: A phase 1 study of JBH492, an anti C-C chemokine receptor 7 antibody-drug conjugate (anti-CCR7 ADC), assessing safety and efficacy in lymphoid malignancies
P. Abrisqueta, R. Marks, I. Avivi, M. Wermke +16 more
2024Cancer Research3 citations
Semantic Scholar
Ibrutinib and R-GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma of non-GCB type: Phase II clinical trial of the Spanish GELTAMO group.
Beatriz Rey Búa, C. Grande, J. S. Sánchez Blanco, P. Abrisqueta +16 more
2024Clinical Cancer Research3 citations
Semantic Scholar
Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.
N. Gower, P. Feugier, J. Westin, Jean-Marc Schiano de Colella +38 more
2026Blood2 citations Open access
Semantic Scholar
Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 7
Lori Leslie, G. Musuraca, P. Abrisqueta, Joshua D. Brody +12 more
2025Blood2 citations
Semantic Scholar
Prognostic factors and effect modifiers in patients with relapsed or refractory follicular lymphoma who failed at least two lines of therapy: a systematic literature and expert clinical review
P. Abrisqueta, A. Jiménez-Ubieto, Á. Serna, I. Zamanillo +16 more
2025Annals of Hematology2 citations
Semantic Scholar
DURABLE EFFICACY WITH FIXED‐DURATION EPCORITAMAB + POLATUZUMAB, VEDOTIN, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA‐R‐CHP) FOR 1L DLBCL (EPCORE NHL‐5)
D. Lavie, D. A. Kerr, A. Avigdor, I. Avivi +14 more
2025Hematological Oncology2 citations
Semantic Scholar
New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group
M. Bastos-Oreiro, P. Abrisqueta, Antonio-M. Gutierrez, Ana Jiménez Ubieto +18 more
2024HemaSphere2 citations Open access
Semantic Scholar
Low‐risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study
A. Muntañola, María Teresa Villalobos, S. González-Villambrosia, M. Rodríguez-Salazar +20 more
2023British Journal of Haematology2 citations Open access
Semantic Scholar
Five-year subgroup analysis of tafasitamab + lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma.
J. Duell, P. Abrisqueta, M. Dreyling, G. Gaidano +10 more
2023Journal of Clinical Oncology2 citations
Semantic Scholar
Epcoritamab (epcor) + chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) eligible for autologous stem cell transplant (ASCT): Pooled results from arms 4 and 10 of EPCORE NHL-2.
Y. Karimi, P. Abrisqueta, C. Andreadis, Che-Ah Y. Chan +13 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
Identification of two epitypes of IGHV unmutated chronic lymphocytic leukemia with distinct B‐cell‐related epigenetic imprinting and genetic alterations
S. Charalampopoulou, S. Ramos-Campoy, M. Duran-Ferrer, A. Puiggros +21 more
2026HemaSphere1 citations Open access
Semantic Scholar
Exploring the synergy between telomere length and genomic complexity in CLL
S. Ramos-Campoy, A. Puiggros, J. Kamaso, H. Parker +16 more
2026British Journal of Haematology1 citations Open access
Semantic Scholar
Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study
Eleonora Roncaglia, E. Gaffo, G. Calabretto, M. Fürstenau +48 more
2025Journal of Hematology & Oncology1 citations Open access
Semantic Scholar
A low lymphocyte‐to‐monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis
P. Mozas, Romain Ould Ammar, L. Chartier, L. Nastoupil +21 more
2025British Journal of Haematology1 citations
Semantic Scholar
Laboratory Prognostic Index (LAB-PI) in diffuse large B-cell lymphoma: a single blood analysis predicts outcomes as good as IPI, NCCN-IPI, and GELTAMO-IPI
F. Martín-Moro, L. Bento, J. Marquet, S. F. Browne-Arthur +19 more
2025ESMO Open1 citations
Semantic Scholar
Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.
Franck Morschhauser, Gilles Salles, Laurie H. Sehn, Alex F. Herrera +33 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar
Mosunetuzumab (Mosun) or glofitamab (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)
C. Andreadis, I. Avivi, Neta Goldschmidt, William Townsend +19 more
2025Blood1 citations
Semantic Scholar
IMPACT OF ASCT CONSOLIDATION AND RITUXIMAB MAINTENANCE ON SURVIVAL IN REAL‐WORLD PATIENTS WITH MANTLE CELL LYMPHOMA IN SPAIN. THE GELTAMO‐MCL‐2022 STUDY
A. Marín-Niebla, M. Bastos-Oreiro, A. Pérez, A. Cabirta-Touzón +34 more
2025Hematological Oncology1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Córdoba×10
Invite
R. Córdoba — researcher profile on SciRah
A. Martin Garcia-Sancho×9
Invite
A. Martin Garcia-Sancho — researcher profile on SciRah
G. Iacoboni×8
Invite
G. Iacoboni — researcher profile on SciRah
F. Bosch×8
Invite
F. Bosch — researcher profile on SciRah

M. Bastos-Oreiro

×8

Invite

M. Bastos-Oreiro — researcher profile on SciRah

A. Jiménez-Ubieto×8

Invite

A. Jiménez-Ubieto — researcher profile on SciRah

Invite

P. Barba — researcher profile on SciRah

Invite

A. Sureda — researcher profile on SciRah

Invite

L. Falchi — researcher profile on SciRah

Invite

S. de Vos — researcher profile on SciRah

Invite

D. Belada — researcher profile on SciRah

Invite

Á. Serna — researcher profile on SciRah